Pfizer logo

With our 170-year legacy of helping patients, Pfizer is committed to providing immunoglobulin (Ig) treatment options to patients who rely on them.

Panzyga Logo

Important Safety Information

Indications and Usage

PANZYGA (Immune Globulin Intravenous [Human] – ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older, chronic immune thrombocytopenia (cITP) in adults and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.

PANZYGA is a liquid medicine for infusion that contains immunoglobulin G (IgG), which are proteins that help fight infection. It is made from human plasma that is donated by healthy people and contains antibodies. For patients with PI, PANZYGA helps replace the missing antibodies in the body. For patients with cITP, PANZYGA helps the body maintain more platelets (the blood cells that help blood clot) to control or prevent bleeding. For patients with CIDP, PANZYGA may help improve mobility and hand strength.

PANZYGA is given into a vein (intravenously) in a hospital, infusion center, doctor’s office, or at home by a trained healthcare provider (HCP).

Selected Safety Information

Do not use PANZYGA if you:

What should I know before taking PANZYGA?

PANZYGA can cause serious side effects. If any of the following problems occur after starting PANZYGA, stop the infusion immediately and contact your HCP or call emergency services:

What are the possible or reasonably likely side effects for PANZYGA?

Pfizer is proud to support the lg community with a commitment to helping meet the diverse treatment needs of patients.

Product Description

Pfizer Pledge Warranty Program

Patient Assistance

Patient Videos